喀什上环哪些医院便宜喀什紧缩术,喀什怀孕二个月不要了怎么办,喀什怀孕67多天了不想要怎么办,喀什男人检查精子质量,喀什包茎如何手术,喀什看包皮手术多少价钱,喀什包皮手术后需要住院吗

SAN FRANCISCO, Sept. 13 (Xinhua) -- Researchers in San Francisco, U.S. have found in a latest study that bisphenol A (BPA) and methylparaben, two chemicals commonly used in consumer products, can interfere with the breast cancer drugs, local media reported on Tuesday.In the study, doctors from California Pacific Medical Center in San Francisco found that healthy breast cells from high-risk patients started to find ways to bypass breast cancer drugs after they were exposed to BPA and methylparaben in the lab.The cells exposed to the two chemicals kept growing and didn't die after they were introduced with Tamoxifen, a current standard drug therapy for female breast cancer and most common used treatment for male breast cancer, Dr. William Goodson, lead author of the study, told San Francisco Chronicle.Goodson said that BPA and methylparaben not only mimic estrogen 's ability to drive cancer, but appear to be even better than the natural hormone in bypassing the ability of drugs to treat it. The finds have been published online in the British medical journal Carcinogenesis.The research shows more evidence of safety issues of BPA, a chemical primarily used to make plastic baby bottles, food containers, household electronics and etc, as well as the less known methylparaben, a chemical preservative used in cosmetics and other personal care products.The researchers noted that the breast cancer rates have been growing by about the same amount in men as in women over the past three decades. Scientists have been looking at environmental causes for the disease and wondering where the hormones are coming from.Goodson said BPA and methylparaben are used so widely and even found in household dust, noting that it is still unknown whether the effects of exposure to the chemicals are reversible.Since 2008, several governments issued reports questioning the negative health effects of BPA, especially raising concerns regarding exposure of fetuses, infants and children. BPA use has been banned in baby bottles in a lot of countries and regions.As for methylparaben, the U.S. Food and Drug Administration said on its website that "at the present time there is no reason for consumers to be concerned about the uses of cosmetics containing parabens (including methylparaben)."

TOKYO, Sept. 23 (Xinhua) -- Japan's H-2A rocket carrying a new information gathering satellite was launched at the Tanegashima Space Center in Kagoshima Prefecture on Friday, local media reported.Japan has already introduced three information-gathering satellites in the wake of a missile launch by Democratic People's Republic of Korea, and the latest one will replace the No. 2 satellite which has passed its use-by date, Kydo News said.Japan's H-2A rocket lifts off from the launchiung pad at the Tanegashima space centre in Kagoshima prefecture, Japan's southern island of Kyushu on September 23, 2011. Japan launched a new spy satellite into orbit September 23, officials saidThe development cost of the fourth satellite has reached 35.9 billion yen and its launch expenses have come to 10.4 billion yen, according to the government.The Japan Aerospace Exploration Agency and Mitsubishi Heavy Industries Ltd. were forced to put off the launch three times during the past four weeks due to the approach of a powerful typhoon and discovery of a system glitch. The rocket was initially scheduled to be sent into orbit on Aug. 28.

BEIJING, Aug. 31 (Xinhuanet) – The pressure of modern society is taking a toll on sexual satisfaction, experts say following the release of an online survey.About 34 percent of people polled in the survey said that they are unsatisfied with their sex lives, with 6.5 percent "very unsatisfied".Another 32 percent condemned their sex lives as "just so-so".The survey interviewed more than 3,000 people, aged between 15 and 55, with men accounting for 74 percent of the interviewees.It was conducted by the China Population Communication Center and the Shanghai Academy of Social Sciences from May 1 to June 20. The survey did not give a margin of error.Only 23 percent of respondents said that they are "satisfied" with their sex lives, with 3.6 percent "very satisfied", according to the survey.But women seem to have a higher rate of satisfaction than men, with only 26 percent saying they are unsatisfied. The rate for men is 42 percent.The rate of sexual satisfaction among Chinese people is below the global average of 44 percent, according to an earlier survey by Durex. The 2007 Durex Global Sexual Wellbeing Survey questioned more than 26,000 people in 26 countries about all aspects of their sex lives - including satisfaction levels.Jiang Hui, president-elect of the Chinese Society of Andrology, attributed the lower rate of sexual satisfaction among Chinese people to rapid economic growth, which inevitably increases work and social pressure.Health problems associated with a modern lifestyle, such as diabetes and hypertension, are also to blame, he said.Jiang said his department of andrology used to receive about 10 patients a day 10 years ago. Now the figure has risen to more than 250.Rising awareness of sex and a more open attitude toward the once-taboo topic among the public also contributed to higher sexual expectations, he said.The survey also revealed that about 30 percent of respondents in the 35-55 age group had sex less than once a week."That rate is quite low, compared with the global average of 103 times a year, or 1.98 times a week," said Yang Xiong, who heads the social survey center at the Shanghai Academy of Social Sciences.Only 16.9 percent of respondents said that they had sex more than 10 times a month. Most respondents had sex three to nine times every month.About 8 percent of respondents said that they basically had no sex at all or it was too infrequent to be classified.The survey seemed to find that the more you made, the less you had. Those who earned at least 9,000 yuan (,400) a month had less sex than those who earned less, according to the survey.Among those making more than 9,000 yuan per month, over 70 percent said they had sex less than twice a month, compared with 16.5 percent for those with a monthly salary of less than 6,000 yuan.The survey also found that when people run into problems with their sex lives, 83 percent turn to the Internet, rather than professionals, for help. Less than 6 percent said they would see doctors to solve sex-related problems.Nearly 70 percent of those polled said they suffered from sexual health problems, such as erectile dysfunction (ED)."Many patients, especially men, are reluctant to see a doctor, which they think harms their manhood," Jiang said.According to a study conducted by the Chinese Society of Andrology, at least 40 percent of men aged 40 and above suffered from erectile dysfunction, roughly the global average.But Yang, from the Shanghai academy, noted that surveys conducted online tend to produce far different results than those conducted face-to-face.He expressed reservations about the survey's accuracy and said the public should only use the results for reference.

PARIS, Aug. 19 (Xinhua) -- Marine scientists and representatives from the private sector and military establishments would meet at UNESCO at the end of this month to measure noise's impact on marine life, the Paris-based UN scientific branch UNESCO said Friday.The main agenda of the meeting, which is due from Aug. 30 to Sep. 1, was to discuss the program of the International Quiet Ocean Experiment (IQOE)."This decade-long project aims to fill the considerable knowledge gaps in this area, so that management of ocean noise can be more informed and effective," UNESCO said in a statement.The Quiet Ocean Experiments was initiated against the background that human activities on the high seas have increased significantly in recent decades, and resulted in impact upon many marine species relying mainly on sound to communicate.However, some sounds are suspected to alter the behavior of marine animals. For example, several whale species have raised the volume of the squeaks, clicks and moans by which they communicate with each other.The experiment is organized by the Scientific Committee on Oceanic Research (SCOR) and the Partnership for Observation of the Global Oceans (POGO), of which UNESCO's Intergovernmental Oceanographic Commission (IOC) is a member.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.